ZA200401605B - Systems and methods for targeted magnetic resonance imaging of the vascular system. - Google Patents
Systems and methods for targeted magnetic resonance imaging of the vascular system. Download PDFInfo
- Publication number
- ZA200401605B ZA200401605B ZA200401605A ZA200401605A ZA200401605B ZA 200401605 B ZA200401605 B ZA 200401605B ZA 200401605 A ZA200401605 A ZA 200401605A ZA 200401605 A ZA200401605 A ZA 200401605A ZA 200401605 B ZA200401605 B ZA 200401605B
- Authority
- ZA
- South Africa
- Prior art keywords
- contrast agent
- targeted
- mri contrast
- vascular
- targeted mri
- Prior art date
Links
- 230000002792 vascular Effects 0.000 title claims description 351
- 238000000034 method Methods 0.000 title claims description 174
- 238000002595 magnetic resonance imaging Methods 0.000 title description 135
- 239000002616 MRI contrast agent Substances 0.000 claims description 259
- 239000002872 contrast media Substances 0.000 claims description 164
- 210000004369 blood Anatomy 0.000 claims description 123
- 239000008280 blood Substances 0.000 claims description 123
- 239000003795 chemical substances by application Substances 0.000 claims description 76
- 241000124008 Mammalia Species 0.000 claims description 73
- 208000007536 Thrombosis Diseases 0.000 claims description 68
- 229920001222 biopolymer Polymers 0.000 claims description 34
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 22
- 238000010494 dissociation reaction Methods 0.000 claims description 19
- 230000005593 dissociations Effects 0.000 claims description 19
- 210000004027 cell Anatomy 0.000 claims description 17
- 102000004895 Lipoproteins Human genes 0.000 claims description 16
- 108090001030 Lipoproteins Proteins 0.000 claims description 16
- 238000001802 infusion Methods 0.000 claims description 16
- 230000003143 atherosclerotic effect Effects 0.000 claims description 15
- 238000004364 calculation method Methods 0.000 claims description 15
- 230000003902 lesion Effects 0.000 claims description 15
- 239000002245 particle Substances 0.000 claims description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 102000009123 Fibrin Human genes 0.000 claims description 12
- 108010073385 Fibrin Proteins 0.000 claims description 12
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 12
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 12
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 12
- 229950003499 fibrin Drugs 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- VMSLCPKYRPDHLN-UHFFFAOYSA-N (R)-Humulone Chemical compound CC(C)CC(=O)C1=C(O)C(CC=C(C)C)=C(O)C(O)(CC=C(C)C)C1=O VMSLCPKYRPDHLN-UHFFFAOYSA-N 0.000 claims description 8
- 102000008186 Collagen Human genes 0.000 claims description 8
- 108010035532 Collagen Proteins 0.000 claims description 8
- 208000005189 Embolism Diseases 0.000 claims description 8
- 108010049003 Fibrinogen Proteins 0.000 claims description 8
- 102000008946 Fibrinogen Human genes 0.000 claims description 8
- 102000006395 Globulins Human genes 0.000 claims description 8
- 108010044091 Globulins Proteins 0.000 claims description 8
- 102000003886 Glycoproteins Human genes 0.000 claims description 8
- 108090000288 Glycoproteins Proteins 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 208000001435 Thromboembolism Diseases 0.000 claims description 8
- 229920001436 collagen Polymers 0.000 claims description 8
- 229940012952 fibrinogen Drugs 0.000 claims description 8
- 150000004676 glycans Chemical class 0.000 claims description 8
- 150000002632 lipids Chemical class 0.000 claims description 8
- 229920001282 polysaccharide Polymers 0.000 claims description 8
- 239000005017 polysaccharide Substances 0.000 claims description 8
- WSNMPAVSZJSIMT-UHFFFAOYSA-N COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 Chemical compound COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 WSNMPAVSZJSIMT-UHFFFAOYSA-N 0.000 claims description 7
- HZHFFEYYPYZMNU-UHFFFAOYSA-K gadodiamide Chemical compound [Gd+3].CNC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC(=O)NC HZHFFEYYPYZMNU-UHFFFAOYSA-K 0.000 claims description 5
- GFSTXYOTEVLASN-UHFFFAOYSA-K gadoteric acid Chemical compound [Gd+3].OC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 GFSTXYOTEVLASN-UHFFFAOYSA-K 0.000 claims description 5
- DPNNNPAKRZOSMO-UHFFFAOYSA-K gadoteridol Chemical compound [Gd+3].CC(O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 DPNNNPAKRZOSMO-UHFFFAOYSA-K 0.000 claims description 5
- HBEAOBRDTOXWRZ-UHFFFAOYSA-K gadoversetamide Chemical compound [Gd+3].COCCNC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC(=O)NCCOC HBEAOBRDTOXWRZ-UHFFFAOYSA-K 0.000 claims description 5
- 229960002059 gadoversetamide Drugs 0.000 claims description 5
- MXZROTBGJUUXID-UHFFFAOYSA-I [Gd+3].[O-]C(=O)CN(CC([O-])=O)CCN(CC(=O)[O-])CCN(CC([O-])=O)C(C([O-])=O)COCC1=CC=CC=C1 Chemical compound [Gd+3].[O-]C(=O)CN(CC([O-])=O)CCN(CC(=O)[O-])CCN(CC([O-])=O)C(C([O-])=O)COCC1=CC=CC=C1 MXZROTBGJUUXID-UHFFFAOYSA-I 0.000 claims description 4
- PCZHWPSNPWAQNF-LMOVPXPDSA-K 2-[[(2s)-2-[bis(carboxylatomethyl)amino]-3-(4-ethoxyphenyl)propyl]-[2-[bis(carboxylatomethyl)amino]ethyl]amino]acetate;gadolinium(3+);hydron Chemical compound [Gd+3].CCOC1=CC=C(C[C@@H](CN(CCN(CC(O)=O)CC([O-])=O)CC([O-])=O)N(CC(O)=O)CC([O-])=O)C=C1 PCZHWPSNPWAQNF-LMOVPXPDSA-K 0.000 claims description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 3
- 241001137251 Corvidae Species 0.000 claims 2
- 235000015108 pies Nutrition 0.000 claims 2
- ABYZSYDGJGVCHS-ZETCQYMHSA-N (2s)-2-acetamido-n-(4-nitrophenyl)propanamide Chemical compound CC(=O)N[C@@H](C)C(=O)NC1=CC=C([N+]([O-])=O)C=C1 ABYZSYDGJGVCHS-ZETCQYMHSA-N 0.000 claims 1
- XRMDCWJNPDVAFI-UHFFFAOYSA-N 2,2,6,6-tetramethyl-1-oxopiperidin-1-ium-4-ol Chemical compound CC1(C)CC(O)CC(C)(C)[N+]1=O XRMDCWJNPDVAFI-UHFFFAOYSA-N 0.000 claims 1
- 235000008375 Decussocarpus nagi Nutrition 0.000 claims 1
- 244000309456 Decussocarpus nagi Species 0.000 claims 1
- 101000617550 Dictyostelium discoideum Presenilin-A Proteins 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 229910052689 Holmium Inorganic materials 0.000 claims 1
- 241000257303 Hymenoptera Species 0.000 claims 1
- 241001538234 Nala Species 0.000 claims 1
- 101100005280 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cat-3 gene Proteins 0.000 claims 1
- 101150045055 PCSK2 gene Proteins 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 125000001261 isocyanato group Chemical group *N=C=O 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 description 31
- 239000007924 injection Substances 0.000 description 31
- 210000001519 tissue Anatomy 0.000 description 24
- 238000003384 imaging method Methods 0.000 description 21
- 208000024172 Cardiovascular disease Diseases 0.000 description 20
- 210000001367 artery Anatomy 0.000 description 20
- 210000004731 jugular vein Anatomy 0.000 description 20
- 210000001715 carotid artery Anatomy 0.000 description 16
- 210000003462 vein Anatomy 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 14
- 230000005291 magnetic effect Effects 0.000 description 12
- 210000004204 blood vessel Anatomy 0.000 description 11
- 208000037998 chronic venous disease Diseases 0.000 description 11
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 10
- 238000012800 visualization Methods 0.000 description 10
- 208000031481 Pathologic Constriction Diseases 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 230000036262 stenosis Effects 0.000 description 8
- 208000037804 stenosis Diseases 0.000 description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 7
- 230000033001 locomotion Effects 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 5
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 238000002583 angiography Methods 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 229960003299 ketamine Drugs 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 5
- 229960001412 pentobarbital Drugs 0.000 description 5
- 238000012805 post-processing Methods 0.000 description 5
- 241000700199 Cavia porcellus Species 0.000 description 4
- 229910052688 Gadolinium Inorganic materials 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 4
- 238000011587 new zealand white rabbit Methods 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 229960004072 thrombin Drugs 0.000 description 4
- 230000008859 change Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- LGMLJQFQKXPRGA-VPVMAENOSA-K gadopentetate dimeglumine Chemical compound [Gd+3].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O LGMLJQFQKXPRGA-VPVMAENOSA-K 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229960003766 thrombin (human) Drugs 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 2
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000011503 in vivo imaging Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 238000010244 region-of-interest analysis Methods 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 238000007794 visualization technique Methods 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 101100309713 Arabidopsis thaliana SD129 gene Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 101100194326 Caenorhabditis elegans rei-2 gene Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000012307 MRI technique Methods 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- -1 USPIOs and MIONSs) Substances 0.000 description 1
- 241001300078 Vitrea Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000010968 computed tomography angiography Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002536 laser-induced breakdown spectroscopy Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000005415 magnetization Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000012987 post-synthetic modification Methods 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000008001 rakum palm Nutrition 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
- A61B5/414—Evaluating particular organs or parts of the immune or lymphatic systems
- A61B5/416—Evaluating particular organs or parts of the immune or lymphatic systems the spleen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- High Energy & Nuclear Physics (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30869001P | 2001-07-30 | 2001-07-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200401605B true ZA200401605B (en) | 2005-04-05 |
Family
ID=23194994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200401605A ZA200401605B (en) | 2001-07-30 | 2004-02-26 | Systems and methods for targeted magnetic resonance imaging of the vascular system. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7412279B2 (zh) |
| EP (1) | EP1420689A4 (zh) |
| JP (3) | JP2004536649A (zh) |
| KR (1) | KR20040018529A (zh) |
| CN (1) | CN1635855A (zh) |
| AU (1) | AU2002322789C1 (zh) |
| BR (1) | BR0211607A (zh) |
| CA (1) | CA2455210A1 (zh) |
| HU (1) | HUP0401548A3 (zh) |
| IL (1) | IL159937A0 (zh) |
| MX (1) | MXPA04000955A (zh) |
| PL (1) | PL366736A1 (zh) |
| TW (1) | TWI221406B (zh) |
| WO (1) | WO2003011113A2 (zh) |
| ZA (1) | ZA200401605B (zh) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004013161A2 (en) * | 2002-08-06 | 2004-02-12 | Epix Pharmaceuticals, Inc. | Peptide aggregates |
| AU2003273242A1 (en) * | 2002-08-27 | 2004-03-19 | Xavier Golay (Nmi) | Microvascular blood volume magnetic resonance imaging |
| EP1420367A1 (en) * | 2002-11-15 | 2004-05-19 | MeVis GmbH | A method for coloring of voxels and image data processing and visualization system |
| AR047692A1 (es) * | 2003-07-10 | 2006-02-08 | Epix Medical Inc | Imagenes de blancos estacionarios |
| US20060052690A1 (en) * | 2004-09-08 | 2006-03-09 | Sirohey Saad A | Contrast agent imaging-driven health care system and method |
| CA2596863A1 (en) * | 2005-02-03 | 2006-08-10 | Epix Pharmaceuticals, Inc. | Steady state perfusion methods |
| WO2006122203A1 (en) * | 2005-05-11 | 2006-11-16 | The University Of Houston System | An intraluminal magneto sensor system and method of use |
| US20090295385A1 (en) * | 2005-05-11 | 2009-12-03 | Audrius Brazdeikis | Magneto Sensor System and Method of Use |
| US8380279B2 (en) * | 2005-05-11 | 2013-02-19 | The University Of Houston System | Intraluminal multifunctional sensor system and method of use |
| WO2007035871A1 (en) * | 2005-09-21 | 2007-03-29 | Massachusetts Institute Of Technology | Systems and methods for tuning properties of nanoparticles |
| US20070293656A1 (en) * | 2005-12-29 | 2007-12-20 | Epix Pharmaceuticals, Inc. | Collagen binding peptides |
| US20070237372A1 (en) * | 2005-12-29 | 2007-10-11 | Shoupu Chen | Cross-time and cross-modality inspection for medical image diagnosis |
| WO2007107931A2 (en) * | 2006-03-17 | 2007-09-27 | Koninklijke Philips Electronics N.V. | Combining magnetic resonance images |
| DE102006018413A1 (de) * | 2006-04-20 | 2007-10-25 | Siemens Ag | MR-Tomograph mit einem System zur Kontrastoptimierung von MRT-Bildern |
| DE102006037284B4 (de) * | 2006-08-09 | 2015-11-26 | Siemens Aktiengesellschaft | Verfahren und Vorrichtung zur Darstellung von Myokardgeweben unterschiedlicher Schädigungszustände |
| JP4936864B2 (ja) * | 2006-11-22 | 2012-05-23 | 株式会社東芝 | 磁気共鳴イメージング装置 |
| US10098563B2 (en) | 2006-11-22 | 2018-10-16 | Toshiba Medical Systems Corporation | Magnetic resonance imaging apparatus |
| EP2234647A4 (en) * | 2008-01-04 | 2014-04-16 | Univ Ohio State Res Found | METHOD OF IN VIVO CHARACTERIZATION OF ATHEROSCLEROTIC PLAQUE BASED ON MAGNETIC RECEPTION TO IDENTIFY SYMPTOMATIVE PLAQUE |
| US8557290B2 (en) * | 2008-03-14 | 2013-10-15 | Northwestern University | Multifunction nanoconjugates for imaging applications and targeted treatment |
| EP2161064A1 (en) | 2008-08-26 | 2010-03-10 | SICCE S.p.A. | Filtering device for ponds and the like |
| US20100137711A1 (en) * | 2008-11-25 | 2010-06-03 | Trustees Of Boston University | Apparatus and Method of Analyzing Arterial Plaque |
| WO2010121133A2 (en) | 2009-04-17 | 2010-10-21 | The General Hospital Corporation | Multimodal imaging of fibrin |
| CA2754390A1 (en) | 2009-03-19 | 2010-09-23 | Wyeth Llc | Methods for the preparation of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)ethyl]phosphonic acid and precursors thereof |
| KR101049915B1 (ko) * | 2009-09-14 | 2011-07-15 | 울산대학교 산학협력단 | 혈관 내 초음파 영상을 이용한 혈관 내 죽상 경화반 성분 측정 장치 및 방법 |
| CN102188722A (zh) * | 2010-03-18 | 2011-09-21 | 中国科学院福建物质结构研究所 | 一种含二价铁的磁共振成像造影剂 |
| US9046593B2 (en) * | 2011-12-15 | 2015-06-02 | The Boeing Company | Method and apparatus for detecting and classifying signals |
| US9849201B2 (en) | 2013-05-03 | 2017-12-26 | Washington University | Homing agents |
| CN103519809B (zh) * | 2013-10-22 | 2015-11-04 | 深圳先进技术研究院 | 氧代谢参数估测方法和系统 |
| WO2015084301A1 (en) * | 2013-12-02 | 2015-06-11 | Northwestern University | Acquiring weighted data using single contrast dose |
| US9514530B2 (en) | 2014-04-16 | 2016-12-06 | Heartflow, Inc. | Systems and methods for image-based object modeling using multiple image acquisitions or reconstructions |
| US9058692B1 (en) * | 2014-04-16 | 2015-06-16 | Heartflow, Inc. | Systems and methods for image-based object modeling using multiple image acquisitions or reconstructions |
| KR101535385B1 (ko) * | 2014-06-17 | 2015-07-08 | 연세대학교 산학협력단 | 자기 공명 영상 촬영 장치 및 방법 |
| DE102015203181A1 (de) * | 2015-02-23 | 2016-08-25 | Karl-Franzens-Universität Graz | Verfahren zur zeitlichen und räumlichen Interpolation von fMRI-Zeitreihen in Bezug auf ein Einzelsubjekt |
| CA2995210A1 (en) | 2015-08-13 | 2017-02-16 | The General Hospital Corporation | Manganese-based chelate conjugates for molecular mr imaging |
| CN108430520B (zh) * | 2015-11-06 | 2021-08-13 | 威斯康星校友研究基金会 | 长效钆基肿瘤靶向成像与治疗剂 |
| WO2017147418A1 (en) | 2016-02-24 | 2017-08-31 | Ohio State Innovation Foundation | Methods and devices for contrast agent magnetic resonance imaging |
| KR102581945B1 (ko) * | 2017-02-07 | 2023-09-25 | 삼성전자주식회사 | 스킨 정보 제공 방법 및 이를 지원하는 전자 장치 |
| CN106986920A (zh) * | 2017-03-09 | 2017-07-28 | 北京市心肺血管疾病研究所 | 四型胶原作为靶点在早期诊断主动脉瘤/夹层中的应用 |
| TW202027028A (zh) | 2018-08-15 | 2020-07-16 | 美商超精細研究股份有限公司 | 用於抑制磁共振影像中之假像之深度學習技術 |
| US11344219B2 (en) | 2019-03-14 | 2022-05-31 | Hyperfine Operations, Inc. | Deep learning techniques for alignment of magnetic resonance images |
| DE102019203714B4 (de) * | 2019-03-19 | 2020-10-22 | Siemens Healthcare Gmbh | Verfahren und Datenverarbeitungssystem zum Bereitstellen von Entscheidungsunterstützungsdaten |
| CN112426143B (zh) * | 2020-11-16 | 2021-07-23 | 清华大学 | 一种肾动脉及腹主动脉一站式无创磁共振血管壁成像系统 |
| CN114663362B (zh) * | 2022-03-04 | 2024-03-29 | 强联智创（北京）科技有限公司 | 一种融合方法、装置以及设备 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4880008A (en) * | 1985-05-08 | 1989-11-14 | The General Hospital Corporation | Vivo enhancement of NMR relaxivity |
| US4777957A (en) * | 1985-06-14 | 1988-10-18 | General Electric Company | Method for measuring and imaging fluid flow |
| EP0247156B1 (en) * | 1985-11-18 | 1993-06-23 | Access Pharmaceuticals Inc. | Polychelating agents for image and spectral enhancement (and spectral shift) |
| DE3786000T3 (de) | 1986-08-18 | 1997-08-21 | Dow Chemical Co | Conjugate dichter Sterne. |
| US5681543A (en) * | 1988-02-29 | 1997-10-28 | Shering Aktiengesellschaft | Polymer-bonded complexing agents and pharmaceutical agents containing them for MRI |
| GB8808305D0 (en) * | 1988-04-08 | 1988-05-11 | Nycomed As | Compositions |
| US5914095A (en) * | 1989-04-07 | 1999-06-22 | Salutar, Inc. | Polychelants containg amide bonds |
| US5695739A (en) * | 1989-06-30 | 1997-12-09 | Schering Aktiengesellschaft | Derivatized DTPA complexes, pharmaceutical agents containing these compounds, their use, and processes for their production |
| US5650133A (en) * | 1990-01-19 | 1997-07-22 | Nycomed Salutar | Macrocyclic polyaza dichelates linked through ring nitrogens via an amide or ester functionality |
| GB9320277D0 (en) | 1993-10-01 | 1993-11-17 | Nycomed Salutar Inc | Chelants |
| CA2069886A1 (en) | 1989-10-23 | 1991-04-24 | David Love | Multi-site metal chelating agents |
| DE3938992A1 (de) * | 1989-11-21 | 1991-05-23 | Schering Ag | Kaskadenpolymer-gebundene komplexbildner, deren komplexe und konjugate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel |
| US5631329A (en) | 1990-08-27 | 1997-05-20 | Dendritech, Inc. | Process for producing hyper-comb-branched polymers |
| DE4115789A1 (de) * | 1991-05-10 | 1992-11-12 | Schering Ag | Makrocyclische polymer-komplexbildner, deren komplexe, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel |
| JPH06507904A (ja) * | 1991-05-23 | 1994-09-08 | イマアーレクス・フアーマシユーチカル・コーポレーシヨン | 磁気共鳴画像形成用の油脂可溶化合物 |
| US5522390A (en) * | 1991-11-21 | 1996-06-04 | U.S. Philips Corporation | Magnetic resonance imaging method |
| US5637759A (en) * | 1992-07-30 | 1997-06-10 | The Regents Of The University Of California | Metal-ligating amino acid derivatives for MRI and for peptide synthesis |
| JPH08502261A (ja) * | 1992-10-02 | 1996-03-12 | ダイアテク，インコーポレイテッド | 多重多価抗血栓症剤 |
| US5726304A (en) | 1992-10-30 | 1998-03-10 | The University Of British Columbia | Porphocyanine and CNC-expanded porphyrins |
| US5401493A (en) * | 1993-03-26 | 1995-03-28 | Molecular Biosystems, Inc. | Perfluoro-1H,-1H-neopentyl containing contrast agents and method to use same |
| US5368033A (en) | 1993-04-20 | 1994-11-29 | North American Philips Corporation | Magnetic resonance angiography method and apparatus employing an integration projection |
| US5579767A (en) * | 1993-06-07 | 1996-12-03 | Prince; Martin R. | Method for imaging abdominal aorta and aortic aneurysms |
| US5417213A (en) * | 1993-06-07 | 1995-05-23 | Prince; Martin R. | Magnetic resonance arteriography with dynamic intravenous contrast agents |
| GB9314499D0 (en) | 1993-07-12 | 1993-08-25 | Nycomed Imaging As | Method |
| GB9318550D0 (en) | 1993-09-07 | 1993-10-20 | Nycomed Salutar Inc | Chelants |
| EP0731797B1 (en) * | 1993-12-03 | 1999-09-08 | BRACCO S.p.A. | Paramagnetic chelates for nuclear magnetic resonance diagnosis |
| DE4344460A1 (de) | 1993-12-22 | 1995-06-29 | Schering Ag | Metallkomplexe von dendrimeren Makromolekülen, diese enthaltende diagnostische Mittel sowie Verfahren zur Herstellung der Komplexe und Mittel |
| DE19581517C2 (de) | 1994-03-22 | 2001-01-25 | Asahi Chemical Ind | Verfahren zur Stabilisierung instabiler Enden eines Oxymethylen-Copolymers |
| EP0702677A1 (en) * | 1994-04-08 | 1996-03-27 | BRACCO International B.V. | Aromatic amide compounds and metal chelates thereof |
| US5582814A (en) | 1994-04-15 | 1996-12-10 | Metasyn, Inc. | 1-(p-n-butylbenzyl) DTPA for magnetic resonance imaging |
| GB9407812D0 (en) | 1994-04-20 | 1994-06-15 | Nycomed Salutar Inc | Compounds |
| IT1269839B (it) * | 1994-05-26 | 1997-04-15 | Bracco Spa | Coniugati di acidi biliari, loro derivati con complessi metallici e relativi usi |
| DE4425857A1 (de) * | 1994-07-07 | 1996-01-11 | Schering Ag | Kaskaden-Polymer-Komplexe, Verfahren zur ihrer Herstellung und diese enthaltende pharmazeutische Mittel |
| RU2147243C1 (ru) | 1994-09-27 | 2000-04-10 | Нюкомед Имагинг А/С | Контрастное средство |
| WO1998053855A1 (en) * | 1997-05-30 | 1998-12-03 | Alliance Pharmaceutical Corp. | Methods and apparatus for monitoring and quantifying the movement of fluid |
| US6232295B1 (en) | 1994-10-12 | 2001-05-15 | Jon Faiz Kayyem | Cell-specific contrast agent and gene delivery vehicles |
| TW319763B (zh) | 1995-02-01 | 1997-11-11 | Epix Medical Inc | |
| DE19518222A1 (de) | 1995-05-11 | 1996-11-14 | Schering Ag | Verwendung von polymeren Kontrastmittel mittleren Molekulargewichts zur Differenzierung von benignen und malignen Tumoren mittels moderner bildgebender Verfahren |
| DE19521945A1 (de) | 1995-06-12 | 1996-12-19 | Schering Ag | Kaskadenpolymere mit Iodaromaten |
| DE19525924A1 (de) * | 1995-07-04 | 1997-01-09 | Schering Ag | Kaskaden-Polymer-Komplexe, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel |
| US5888576A (en) * | 1995-07-11 | 1999-03-30 | Nissho Iwai Corporation | Edible shrimp product and method of making |
| WO1997006833A1 (en) | 1995-08-11 | 1997-02-27 | Dendritech, Inc. | Hyper comb-branched polymer conjugates |
| IT1277596B1 (it) | 1995-09-15 | 1997-11-11 | Bracco Spa | Composti macromolecolari di tipo dendrimerico |
| US6638508B2 (en) * | 1995-12-21 | 2003-10-28 | Yeda Research And Development Co., Ltd. | Modified avidin-type molecules as targeting agents for the liver and cells of the reticuloendothelial system |
| CA2242647A1 (en) | 1996-01-10 | 1997-07-17 | Amersham Health As | Contrast media |
| IT1283218B1 (it) | 1996-03-08 | 1998-04-16 | Bracco Spa | Polichelanti, loro complessi con ioni metallici, loro preparazione e loro usi |
| EP0907379B1 (en) | 1996-04-01 | 2004-06-02 | Epix Medical, Inc. | Bioactivated diagnostic imaging contrast agents |
| US6054114A (en) | 1996-05-08 | 2000-04-25 | Massachusetts Institute Of Technology | Organometallic ligands for the localization and quantification of amyloid in vivo and in vitro |
| IT1283650B1 (it) | 1996-08-02 | 1998-04-23 | Bracco Spa | Chelati paramagnetici ad alta relassivita' in siero |
| IT1283651B1 (it) | 1996-08-02 | 1998-04-23 | Bracco Spa | Chelati paramagnetici ad alta relassivita' in siero |
| DE19707708C2 (de) | 1997-02-26 | 2002-01-10 | Infineon Technologies Ag | Strombegrenzungsschaltung |
| WO1998041241A1 (fr) | 1997-03-18 | 1998-09-24 | Nihon Schering K. K. | Milieux de contraste pour irm, reconnaissant les modifications de l'environnement |
| US6061587A (en) * | 1997-05-15 | 2000-05-09 | Regents Of The University Of Minnesota | Method and apparatus for use with MR imaging |
| DE19731300C1 (de) | 1997-07-11 | 1999-01-21 | Schering Ag | Perfluoralkylgruppenhaltige Trijodaromaten, Verfahren zu deren Herstellung und deren Verwendung als Kontrastmittel |
| US6073042A (en) * | 1997-09-25 | 2000-06-06 | Siemens Medical Systems, Inc. | Display of three-dimensional MRA images in which arteries can be distinguished from veins |
| IL134985A0 (en) | 1997-10-02 | 2001-05-20 | Epix Medical Inc | A method for contrast enhanced diagnostic imaging |
| CA2309749A1 (en) | 1997-11-17 | 1999-05-27 | Research Corporation Technologies, Inc. | Magnetic resonance imaging agents for the detection of physiological agents |
| GB2336680A (en) * | 1998-04-25 | 1999-10-27 | Marconi Gec Ltd | Imaging using a contrast agent |
| US6858210B1 (en) | 1998-06-09 | 2005-02-22 | La Jolla Pharmaceutical Co. | Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same |
| WO2000009170A1 (en) | 1998-08-10 | 2000-02-24 | Bracco Research S.A. | Combination of a positive mri contrast agent with a negative mri contrast agent |
| US6112112A (en) * | 1998-09-18 | 2000-08-29 | Arch Development Corporation | Method and system for the assessment of tumor extent in magnetic resonance images |
| US6342598B1 (en) * | 1998-11-26 | 2002-01-29 | Bracco International B.V. | Amphipatic polycarboxylic chelates and complexes with paramagnetic metals as MRI contrast agents |
| US6399578B1 (en) | 1998-12-09 | 2002-06-04 | La Jolla Pharmaceutical Company | Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same |
| US6458953B1 (en) | 1998-12-09 | 2002-10-01 | La Jolla Pharmaceutical Company | Valency platform molecules comprising carbamate linkages |
| CZ2002343A3 (cs) | 1999-07-29 | 2002-08-14 | Epix Medical, Inc. | Cílená multimerní zobrazovací činidla s multilokální vazebnou schopností |
| TWI290146B (en) * | 1999-07-29 | 2007-11-21 | Dyax Corp | Binding moieties for fibrin |
| EP1379885A4 (en) * | 2001-01-05 | 2005-07-06 | Univ Duke | CONTRAST REINFORCING AGENT FOR MAGNETIC RESONANCE IMAGING |
| US6549798B2 (en) | 2001-02-07 | 2003-04-15 | Epix Medical, Inc. | Magnetic resonance angiography data |
| US6459264B1 (en) * | 2001-02-22 | 2002-10-01 | Mayo Foundation For Medical Education And Research | Real-time embedded magnetic resonance fluoroscopy |
| WO2004013161A2 (en) * | 2002-08-06 | 2004-02-12 | Epix Pharmaceuticals, Inc. | Peptide aggregates |
-
2002
- 2002-07-29 TW TW091116939A patent/TWI221406B/zh not_active IP Right Cessation
- 2002-07-30 BR BR0211607-3A patent/BR0211607A/pt not_active Application Discontinuation
- 2002-07-30 EP EP02756807A patent/EP1420689A4/en not_active Withdrawn
- 2002-07-30 PL PL02366736A patent/PL366736A1/xx not_active Application Discontinuation
- 2002-07-30 CN CNA028192532A patent/CN1635855A/zh active Pending
- 2002-07-30 MX MXPA04000955A patent/MXPA04000955A/es not_active Application Discontinuation
- 2002-07-30 CA CA002455210A patent/CA2455210A1/en not_active Abandoned
- 2002-07-30 KR KR10-2004-7001273A patent/KR20040018529A/ko not_active Application Discontinuation
- 2002-07-30 JP JP2003516353A patent/JP2004536649A/ja active Pending
- 2002-07-30 US US10/209,416 patent/US7412279B2/en not_active Expired - Fee Related
- 2002-07-30 WO PCT/US2002/024153 patent/WO2003011113A2/en active Application Filing
- 2002-07-30 IL IL15993702A patent/IL159937A0/xx unknown
- 2002-07-30 HU HU0401548A patent/HUP0401548A3/hu unknown
- 2002-07-30 AU AU2002322789A patent/AU2002322789C1/en not_active Ceased
-
2004
- 2004-02-26 ZA ZA200401605A patent/ZA200401605B/en unknown
-
2005
- 2005-07-27 JP JP2005218095A patent/JP2006006962A/ja not_active Withdrawn
-
2008
- 2008-03-24 JP JP2008076834A patent/JP2008220966A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA04000955A (es) | 2005-02-17 |
| EP1420689A2 (en) | 2004-05-26 |
| BR0211607A (pt) | 2004-08-24 |
| HUP0401548A3 (en) | 2010-01-28 |
| AU2002322789C1 (en) | 2006-10-12 |
| JP2004536649A (ja) | 2004-12-09 |
| WO2003011113A3 (en) | 2003-07-03 |
| PL366736A1 (en) | 2005-02-07 |
| WO2003011113A2 (en) | 2003-02-13 |
| JP2006006962A (ja) | 2006-01-12 |
| CN1635855A (zh) | 2005-07-06 |
| JP2008220966A (ja) | 2008-09-25 |
| TWI221406B (en) | 2004-10-01 |
| AU2002322789B2 (en) | 2006-04-13 |
| HUP0401548A2 (hu) | 2005-08-29 |
| CA2455210A1 (en) | 2003-02-13 |
| EP1420689A4 (en) | 2009-01-28 |
| US7412279B2 (en) | 2008-08-12 |
| IL159937A0 (en) | 2004-06-20 |
| US20030028101A1 (en) | 2003-02-06 |
| KR20040018529A (ko) | 2004-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200401605B (en) | Systems and methods for targeted magnetic resonance imaging of the vascular system. | |
| AU2002322789A1 (en) | Systems and methods for targeted magnetic resonance imaging of the vascular system | |
| Rennert et al. | Image fusion of contrast enhanced ultrasound (CEUS) with computed tomography (CT) or magnetic resonance imaging (MRI) using volume navigation for detection, characterization and planning of therapeutic interventions of liver tumors | |
| Vosshenrich et al. | Contrast-enhanced MR angiography of abdominal vessels: is there still a role for angiography? | |
| Wagner et al. | Effect of butylscopolamine on image quality in MRI of the prostate | |
| US20150050218A1 (en) | Dynamic Contrast Enhanced MRI Method And Agents For The Assessment Of The Macromolecular Transport Within Pathologic Tissues | |
| Dawson et al. | Scaphoid blood flow and acute fracture healing: a dynamic MRI study with enhancement with gadolinium | |
| Lobatto et al. | Imaging the efficacy of anti-inflammatory liposomes in a rabbit model of atherosclerosis by non-invasive imaging | |
| Alonso-Burgos et al. | Preoperative planning of DIEP and SGAP flaps: preliminary experience with magnetic resonance angiography using 3-tesla equipment and blood-pool contrast medium | |
| Ross et al. | Image fusion with volume navigation of contrast enhanced ultrasound (CEUS) with computed tomography (CT) or magnetic resonance imaging (MRI) for post-interventional follow-up after transcatheter arterial chemoembolization (TACE) of hepatocellular carcinomas (HCC): Preliminary results | |
| Su et al. | Investigation of longitudinal vascular changes in control and chemotherapy‐treated tumors to serve as therapeutic efficacy predictors | |
| Zhang et al. | Preoperative T staging of potentially resectable esophageal cancer: a comparison between free-breathing radial VIBE and breath-hold Cartesian VIBE, with Histopathological correlation | |
| Watanabe et al. | The usefulness of 3D MR angiography in surgery for ruptured cerebral aneurysms | |
| Fellner et al. | Fluoroscopically triggered contrast-enhanced 3D MR DSA and 3D time-of-flight turbo MRA of the carotid arteries: first clinical experiences in correlation with ultrasound, x-ray angiography, and endarterectomy findings | |
| Tang et al. | Chronic thromboembolic pulmonary hypertension: Comparison of dual-energy computed tomography and single photon emission computed tomography in canines | |
| Bendib et al. | Assessment of complicated arterial bypass grafts: value of contrast-enhanced subtraction magnetic resonance angiography | |
| AU2006202989B2 (en) | Systems and Methods for Targeted Magnetic Resonance Imaging of the Vascular System | |
| Lin et al. | 3D contrast-enhanced MR portography and direct X-ray portography: a correlation study | |
| Liu et al. | Improved display of abdominal contrast-enhanced MRA using gadobutrol: comparison with Gd-DTPA | |
| Markl et al. | Optimized 3D bright blood MRI of aortic plaque at 3 T | |
| Kurosaki et al. | Application of phase sensitive imaging (PSI) for hemorrhage diagnosis in pituitary adenomas | |
| den Adel et al. | Self-gated CINE MRI for combined contrast-enhanced imaging and wall-stiffness measurements of murine aortic atherosclerotic lesions | |
| Ellingson | Contrast-Enhanced T1-Weighted Digital Subtraction for Increased Lesion Conspicuity and Quantifying Treatment Response in Malignant Gliomas | |
| Zheng et al. | Application of Multi-slice Spiral CT and MRI in Biliary Surgery | |
| Prokop | CT and MR to assess the response of liver tumors to hepatic perfusion |